key: cord-1006060-udnzb9gd
authors: Baskota, Swikrity Upadhyay; Chandra, Ashish; Cross, Paul
title: The practice of cytopathology during the era of COVID-19: challenges and changes
date: 2020-10-12
journal: Diagn Histopathol (Oxf)
DOI: 10.1016/j.mpdhp.2020.10.007
sha: f0ffc5b47312b0d73efad8901edeb0cd0cd3d13d
doc_id: 1006060
cord_uid: udnzb9gd

This paper reviews the challenges faced by cytology laboratories during the COVID-19 pandemic. Various safety guidelines regarding collection, handling, transport and sampling in cytology laboratory are presented. A brief literature overview of adapted changes regarding new safety techniques, processing, sampling techniques implemented by the cytology laboratories in the this part of the world is presented. The use of cytology in COVID-19 patients is discussed. The authors have also tried to present the challenges and changes faced for training and education during this time. Migration from multi-headed scope in-person sign-out to digital based platforms were adapted to continue medical education. The potential long-term implications of these adaptations on cytology services are also touched upon.

In the United States of America (USA), the Centre for Disease Control (CDC) recommends any specimens coming to the cytology lab from suspected or confirmed COVID-19-positive patients to be transported as UN3373 Biological Substance Category B 1 . The packaging for UN3373 consists of 3 components: 1) a leak-proof primary receptacle, 2) a leak-proof secondary packaging, and 3) an outer packaging of adequate strength with at least 1 surface having minimum dimensions of 100 mm × 100 mm. The primary container should also have a patient label and the laboratory request form should be in outer packaging. Use of pneumatic tube systems should be discouraged and all the specimens with suspected or confirmed COVID-19 should be hand delivered. The personnel who transport specimens should be trained in safe handling practices and spill decontamination procedures. As the virus can survive on paper up to 24 hours, efforts should be made for paperless electronic request transmission 2 .

From the literature published so far, it is clear that the major routes of transmission of COVID-19 are person-to-person transmission through air droplets, close contact with an infected individual or touching fomites that have been contaminated 3 . Since many of the cytology specimens have a high likelihood of generating aerosols or droplets, for example all respiratory specimens (such as Broncho alveolar lavages, bronchial brushings, bronchial washings, sputum, pleural fluids, EBUS-guided FNAs, and touch imprint slides from lung core biopsies), appropriate Personal Protective Equipment (PPE) should be worn prior to handling any specimen. PPE includes gloves, surgical masks, water resistant gown and eye protection (goggles or face shield) while processing specimens in a certified Class II Biosafety Cabinet (BSC) (Figure 1 ). When a Class II BSC is not available or when handling samples from patients with suspected or known positive COVID-19, surgical mask and/ or face shield or other physical barriers, like a splash shield are advocated; centrifuge safety cups and sealed centrifuge rotors can be used to reduce the risk of exposure to laboratory personnel. Given the variability in the clinical presentation of COVID-19, all specimens received in a cytology lab should be considered as a high-risk specimen.

Respiratory specimens collected in appropriate containers can be stored at a temperature of While this can increase the specimen handling workload and turn-around time of specimen processing in the cytology lab, the safety of cytotechnologists must be taken into consideration. Since cytology glass slides are usually manually processed by multiple people before arriving at a pathologist's desk for reporting, wearing gloves to avoid contact can be a solution. Dipping the slides in 95% alcohol can be another alternative, but the disadvantage is the alcohol might erase any screening marks put on the slide by the screeners 9 .

COVID-19 virus has been shown to persist on a variety of surfaces for up to 72 hours. Hence, all the surfaces and equipment used in the cytology lab should be frequently decontaminated. The most commonly used and most effective decontaminants are freshly prepared 0.1%-0.5% Sodium hypochlorite solution, 70% ethanol and 0.5% hydrogen peroxide. UV disinfection or a manual spray device can also be used 2 .

Cytology laboratories quickly saw a drastic reduction of screening and diagnostic cytology specimens like pap/cervical smears, fine needle aspiration cytology of thyroid smears, urines and effusions due to J o u r n a l P r e -p r o o f lockdown enforced at most of the places in early spread of the disease. In the initial three weeks of Italian national lockdown, a single institutional study done at cytopathology laboratory of University of Naples 'Federico II', reported a significant reduction of number of thyroid FNAs (p<0.001) from n=229 (37.2%) to n=12 (12.8%) and pap smears (n=216, 35.1% vs n=18, 19.1%; p=0.003) 11 . The experience in our laboratory at University of Pittsburgh Medical Center, USA with Pap smears is also similar from 200 a day to 15-20 a day for the first month of lockdown. Labs in the UK also noted well over a 50% reduction in diagnostic cytology and a reduction to almost zero for routine cervical cytology screening samples (PAC, personal experience; Figure 2 ). It is also necessary for the cytology labs to prepare a mitigation strategy for a rebound increase of these diagnostic and screening cases soon as and when services start to resume to more pre-COVID levels.

The initial decrease in specimen numbers gave an opportunity to the cytology laboratories to evaluate their staffing need, maintain social distancing among the workforce and formulate a plan to optimally operate the lab while meeting the social distancing guidelines. Some laboratories, akin to clinical teams, split their staff into teams and had an alternating on site approach, so that the staff was effectively split into two identical teams, to try and minimize exposure and maximize staff resources and availability.

WHO recommended the establishment of a blame-free environment for laboratory staff to report incidents, encouraging self-assessment and symptom reporting, and arranging appropriate work hours with breaks. If a worker is infected with COVID-19 due to exposure at a work place, WHO further recommends honoring the right to compensation, rehabilitation and curative services and considering it as an occupational exposure, henceforth treating as an occupational disease with adequate emotional support by the management 12 . Current challenges for cytology laboratories are summarised in Box 2.

It has been a challenge to continue rapid on-site evaluation during the COVID-19 outbreak by our cytology frontline staff. However, rapid on-site evaluation (ROSE) helps immediate evaluation of important. It can also be used to assess if the patient has any potential COVID symptoms that may require investigation and reduces the risk of exposure to the pathologist 15 .

The cytologic features of COVID-19 have not been well reported in literature yet. Those that have been reported so far suggest that COVID-19 infection does not produce specific diagnostic changes that are pathognomonic of this infection, but rather those of marked reactive changes. However, it is important to be aware of some of the suggestive features of the presentation of COVID-19. Furthermore, a cytologist's simple observation of respiratory specimens might give a clue to diagnose atypical presentations to treating physicians. A bronchoalveolar lavage (in a patient positive for SARS-CoV-2) showed predominantly large numbers of activated plasma cells (CD138+) with occasional plasmablastic features on the cytologic preparations and immunostaining. Occasional intranuclear cytopathic inclusions and nuclear clearing of alveolar macrophages attributable to SARS-CoV-2 were also documented 16 . The exuberant plasmacytosis implies immune activation which has also been frequently reported in extrinsic allergic alveolitis, drug-induced pneumonia, aspergillosis, lymphomatoid granulomatosis and primary effusion lymphoma. Another case report with bronchoalveolar lavage cytology, in a 34-year-old male with an atypical presentation 17 , did not reveal similar findings. However, J o u r n a l P r e -p r o o f

Centers for Disease Control and Prevention (CDC). Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease

Biosafety in surgical pathology in the era of SARS-Cov2 pandemia. A statement of the Italian Society of Surgical Pathology and Cytology

Rational Use of Personal Protective Equipment for Coronavirus Disease 2019 (COVID-19). Interim Guidance

Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human Cases. Interim Guidance

ECDC Technical Report: Infection Prevention and Control for COVID-19 in Healthcare Settings. ECDC

COVID-19: Safe Handling and Processing for Samples in Laboratories

Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan

Cytologic and histologic samples from patients infected by the novel coronavirus 2019 SARS-CoV-2: An Italian institutional experience focusing on biosafety procedures

The COVID-19 pandemic: implications for the cytology laboratory

Coronavirus Disease (COVID-19) Outbreak: Rights, Roles and Responsibilities of Health Workers, Including Key Considerations for Occupational Safety and Health

Infection Prevention and Control During Health Care When Novel Coronavirus (nCoV) Infection Is Suspected. Interim Guidance

Telecytology for Rapid On-Site Evaluation: Current Status

Thyroid cytology in the times of coronavirus

Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe

Delayed diagnosis of COVID-19 in a 34-year-old man with atypical presentation

Sign: A Distinctive Cytologic Clue to Reactive Pneumocytes

Pulmonary pathology and COVID-19: lessons from